Pharmaceutical compositions

A composition and drug technology, applied in the field of treatment of movement disorders, can solve problems that have not been proved by experiments

Pending Publication Date: 2020-01-14
ADEPTIO PHARMA
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It has been previously assumed that (+)-α-dihydrotetrabenazine is a metabolite of tetrabenazine, primarily responsible f

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical compositions
  • Pharmaceutical compositions
  • Pharmaceutical compositions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0465] A study of the properties of dihydrotetrabenazine metabolites formed after administration of tetrabenazine to human subjects

[0466] Pharmacokinetic studies were performed to determine the plasma concentrations of + / - alpha and + / - beta dihydrotetrabenazine in healthy adult male volunteers following oral administration of 25 mg tablets once and multiple times daily under fasting conditions Level. The data are summarized below.

[0467] Table 1 summarizes the pharmacokinetic data obtained after a single oral dose of tetrabenazine at a dose level of 25 mg (fasted, N=08).

[0468] Table 1

[0469]

[0470] Table 2 summarizes the pharmacokinetic data obtained after multiple oral administrations of tetrabenazine at the 25 mg dose level (fasted, N=07).

[0471] Table 2

[0472]

[0473] The data shown in Tables 1 and 2 indicate that, in humans, the major metabolites are the (-)-α-dihydrotetrabenazine isomer, which is essentially active as a VMAT2 binder, and (+)-β ...

Embodiment 2

[0476] Study of the Effects of Compositions of (+)-α-Dihydrotetrabenazine and (-)-α-Dihydrotetrabenazine on Locomotor Activity and Stereotyped Behavior in Rats

[0477] The effects of a combination of (+)-α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine on locomotor activity and stereotyped behavior in rats were studied and compared with those of (+)- The effects of α-dihydrotetrabenazine and (-)-α-dihydrotetrabenazine isomers were compared.

[0478] Materials and Methods

[0479] Open Fields, Med Associates Inc.

[0480] Plastic syringe 1ml, Terumo. No.: SS-01T1

[0481] Animal gavage needle 15G, Instech Solomon, catalog number: 72-4446

[0482] Sartorius electronic balance A22101, Sartorius Weighting Technology, Germany

[0483] Needle 27G Terumo Myjector, 0.5ml, number: 8300010463

[0484] Plastic syringe 3ml, Soft-Ject, number: 8300005761

[0485] BD Microtainer K2EDTA tube number: 365975

[0486] Matrix 0.75ml, Alphanum tube, Thermo Scientific, number: 4274

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

This invention relates to the use of (+)-beta-dihydrotetrabenazine and combinations of (+)-alpha-dihydrotetrabenazine, (-)-alpha-dihydrotetrabenazine and/or (+)-beta-dihydrotetrabenazine, for the treatment of movement disorders, such as Tourette's syndrome. The invention also provides dosage forms containing said dihydrotetrabenazine isomers.

Description

technical field [0001] The present invention relates to (+)-β-dihydrotetrabenazine and (+)-α-dihydrotetrabenazine, (-)-α-dihydrotetrabenazine and / or (+)-β- Use of a composition of dihydrotetrabenazine for the treatment of movement disorders (Tourette's syndrome). Background technique [0002] Movement disorders can generally be divided into two categories: hyperkinetic movement disorders and hypokinetic movement disorders. Hyperkinetic movement disorders are caused by increased muscle activity and can cause abnormal and / or excessive movements, including tremors, dystonia, chorea, tics, myoclonus, and stereotypic behavior. [0003] Hyperkinetic movement disorders are often psychological in nature, arising from improper regulation of amine neurotransmitters in the basal ganglia. [0004] Tourette syndrome is a specific hyperkinetic movement disorder, an inherited neurological disorder characterized by multiple physical and vocal tics. The tics are usually repetitive, but oc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4747A61K45/06A61P25/14
CPCA61K45/06A61K31/4747A61P25/14A61K2300/00A61K31/435
Inventor 安德鲁·约翰·达菲尔德阿南特·潘迪亚
Owner ADEPTIO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap